📊 SNNC Key Takeaways
Is Sibannac, Inc. (SNNC) a Good Investment?
Sibannac is technically insolvent with negative stockholders equity of -396.1K and liabilities exceeding assets by 396K. The company generates minimal revenue (41K) while operating at catastrophic losses (net loss -103.3K), creating an acute liquidity crisis with current ratio of 0.03x indicating inability to meet obligations.
Why Buy Sibannac, Inc. Stock? SNNC Key Strengths
- No strengths identified
SNNC Stock Risks: Sibannac, Inc. Investment Risks
- Technical insolvency: negative stockholders equity (-396.1K) with liabilities exceeding total assets
- Severe liquidity crisis with current ratio of 0.03x and negative operating cash flow (-7.0K)
- Unsustainable business model generating 41K revenue against 103.3K net loss with negative gross margin of -90.8%
Key Metrics to Watch
- Stockholders equity recovery and capital structure recapitalization
- Revenue generation and path to operational profitability
- Operating cash flow normalization
Sibannac, Inc. (SNNC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SNNC Profit Margin, ROE & Profitability Analysis
SNNC vs Healthcare Sector: How Sibannac, Inc. Compares
How Sibannac, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sibannac, Inc. Stock Overvalued? SNNC Valuation Analysis 2026
Based on fundamental analysis, Sibannac, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sibannac, Inc. Balance Sheet: SNNC Debt, Cash & Liquidity
SNNC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sibannac, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction.
SNNC Revenue Growth, EPS Growth & YoY Performance
SNNC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2017 | $56 | -$18.5K | N/A |
| Q1 2017 | $41.0K | -$33.9K | N/A |
| Q3 2016 | N/A | -$49.0K | N/A |
| Q2 2016 | N/A | -$16.3K | N/A |
| Q1 2016 | N/A | -$7.5K | N/A |
| Q3 2015 | N/A | -$5.5K | N/A |
| Q2 2015 | N/A | -$16.3K | N/A |
| Q3 2014 | $37.9K | -$5.5K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sibannac, Inc. Dividends, Buybacks & Capital Allocation
SNNC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sibannac, Inc. (CIK: 0001313938)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNNC
What is the AI rating for SNNC?
Sibannac, Inc. (SNNC) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNNC's key strengths?
Claude: .
What are the risks of investing in SNNC?
Claude: Technical insolvency: negative stockholders equity (-396.1K) with liabilities exceeding total assets. Severe liquidity crisis with current ratio of 0.03x and negative operating cash flow (-7.0K).
What is SNNC's revenue and growth?
Sibannac, Inc. reported revenue of $41.0K.
Does SNNC pay dividends?
Sibannac, Inc. does not currently pay dividends.
Where can I find SNNC SEC filings?
Official SEC filings for Sibannac, Inc. (CIK: 0001313938) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNNC's EPS?
Sibannac, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNNC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sibannac, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNNC stock overvalued or undervalued?
Valuation metrics for SNNC: ROE of N/A (sector avg: 15%), net margin of -251.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SNNC stock in 2026?
Our dual AI analysis gives Sibannac, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNNC's free cash flow?
Sibannac, Inc.'s operating cash flow is $-7.0K, with capital expenditures of $0.0. FCF margin is -17.0%.
How does SNNC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -251.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).